Literature DB >> 15566280

Synthesis and evaluation of keto-glutamine analogues as potent inhibitors of severe acute respiratory syndrome 3CLpro.

Rajendra P Jain1, Hanna I Pettersson, Jianmin Zhang, Katherine D Aull, Pascal D Fortin, Carly Huitema, Lindsay D Eltis, Jonathan C Parrish, Michael N G James, David S Wishart, John C Vederas.   

Abstract

The 3C-like proteinase (3CL(pro)) of severe acute respiratory syndrome (SARS) coronavirus is a key target for structure-based drug design against this viral infection. The enzyme recognizes peptide substrates with a glutamine residue at the P1 site. A series of keto-glutamine analogues with a phthalhydrazido group at the alpha-position were synthesized and tested as reversible inhibitiors against SARS 3CL(pro). Attachment of tripeptide (Ac-Val-Thr-Leu) to these glutamine-based "warheads" generated significantly better inhibitors (4a-c, 8a-d) with IC(50) values ranging from 0.60 to 70 microM.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15566280     DOI: 10.1021/jm0494873

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  58 in total

1.  Severe acute respiratory syndrome coronavirus papain-like novel protease inhibitors: design, synthesis, protein-ligand X-ray structure and biological evaluation.

Authors:  Arun K Ghosh; Jun Takayama; Kalapala Venkateswara Rao; Kiira Ratia; Rima Chaudhuri; Debbie C Mulhearn; Hyun Lee; Daniel B Nichols; Surendranath Baliji; Susan C Baker; Michael E Johnson; Andrew D Mesecar
Journal:  J Med Chem       Date:  2010-07-08       Impact factor: 7.446

2.  Inhibitors of SARS-3CLpro: virtual screening, biological evaluation, and molecular dynamics simulation studies.

Authors:  Prasenjit Mukherjee; Falgun Shah; Prashant Desai; Mitchell Avery
Journal:  J Chem Inf Model       Date:  2011-05-23       Impact factor: 4.956

3.  Discovery, synthesis, and structure-based optimization of a series of N-(tert-butyl)-2-(N-arylamido)-2-(pyridin-3-yl) acetamides (ML188) as potent noncovalent small molecule inhibitors of the severe acute respiratory syndrome coronavirus (SARS-CoV) 3CL protease.

Authors:  Jon Jacobs; Valerie Grum-Tokars; Ya Zhou; Mark Turlington; S Adrian Saldanha; Peter Chase; Aimee Eggler; Eric S Dawson; Yahira M Baez-Santos; Sakshi Tomar; Anna M Mielech; Susan C Baker; Craig W Lindsley; Peter Hodder; Andrew Mesecar; Shaun R Stauffer
Journal:  J Med Chem       Date:  2013-01-03       Impact factor: 7.446

4.  Long-range cooperative interactions modulate dimerization in SARS 3CLpro.

Authors:  Jennifer Barrila; Usman Bacha; Ernesto Freire
Journal:  Biochemistry       Date:  2006-12-19       Impact factor: 3.162

5.  Perspectives on SARS-CoV-2 Main Protease Inhibitors.

Authors:  Kaifu Gao; Rui Wang; Jiahui Chen; Jetze J Tepe; Faqing Huang; Guo-Wei Wei
Journal:  J Med Chem       Date:  2021-11-19       Impact factor: 8.039

6.  Structure-based design, synthesis, and biological evaluation of a series of novel and reversible inhibitors for the severe acute respiratory syndrome-coronavirus papain-like protease.

Authors:  Arun K Ghosh; Jun Takayama; Yoann Aubin; Kiira Ratia; Rima Chaudhuri; Yahira Baez; Katrina Sleeman; Melissa Coughlin; Daniel B Nichols; Debbie C Mulhearn; Bellur S Prabhakar; Susan C Baker; Michael E Johnson; Andrew D Mesecar
Journal:  J Med Chem       Date:  2009-08-27       Impact factor: 7.446

7.  Design of wide-spectrum inhibitors targeting coronavirus main proteases.

Authors:  Haitao Yang; Weiqing Xie; Xiaoyu Xue; Kailin Yang; Jing Ma; Wenxue Liang; Qi Zhao; Zhe Zhou; Duanqing Pei; John Ziebuhr; Rolf Hilgenfeld; Kwok Yung Yuen; Luet Wong; Guangxia Gao; Saijuan Chen; Zhu Chen; Dawei Ma; Mark Bartlam; Zihe Rao
Journal:  PLoS Biol       Date:  2005-09-06       Impact factor: 8.029

8.  Progress in Anti-SARS Coronavirus Chemistry, Biology and Chemotherapy.

Authors:  Arun K Ghosh; Kai Xi; Michael E Johnson; Susan C Baker; Andrew D Mesecar
Journal:  Annu Rep Med Chem       Date:  2007-02-01       Impact factor: 1.059

Review 9.  A review of the latest research on Mpro targeting SARS-COV inhibitors.

Authors:  Huihui Yang; Jinfei Yang
Journal:  RSC Med Chem       Date:  2021-04-14

Review 10.  Synthetic and computational efforts towards the development of peptidomimetics and small-molecule SARS-CoV 3CLpro inhibitors.

Authors:  Abhik Paul; Arnab Sarkar; Sanjukta Saha; Avik Maji; Pritha Janah; Tapan Kumar Maity
Journal:  Bioorg Med Chem       Date:  2021-07-03       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.